StockData
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc. (LUCD) stock

LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3034% above fair value
$0.40−0.05 (-11.42%)

Close on Nov 16, 2026Market cap $80.85MP/E –Yield –

Lucid Diagnostics r&d expenses

Research and development expenses are spending on new products and technology.

Lucid Diagnostics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.39M, down 7.0% year over year. For fiscal 2025 it was $5.68M, down 5.2% from the year before. The highest annual figure on record is $11.26M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.68M-5.2%
FY2024Dec 31, 2024$5.99M-17.4%
FY2023Dec 31, 2023$7.25M-35.6%
FY2022Dec 31, 2022$11.26M+21.1%
FY2021Dec 31, 2021$9.30M+70.8%
FY2020Dec 31, 2020$5.44M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.19M-5.0%
Q1 FY2026Mar 31, 2026$1.21M-15.5%
Q4 FY2025Dec 31, 2025$1.72M+18.6%
Q3 FY2025Sep 30, 2025$1.27M-23.6%
Q2 FY2025Jun 30, 2025$1.26M-8.5%
Q1 FY2025Mar 31, 2025$1.43M-4.9%
Q4 FY2024Dec 31, 2024$1.45M-24.2%
Q3 FY2024Sep 30, 2024$1.67M+3.2%
Q2 FY2024Jun 30, 2024$1.37M-24.9%
Q1 FY2024Mar 31, 2024$1.50M-20.7%
Q4 FY2023Dec 31, 2023$1.92M-21.5%
Q3 FY2023Sep 30, 2023$1.62M-40.3%
Q2 FY2023Jun 30, 2023$1.83M-46.9%
Q1 FY2023Mar 31, 2023$1.89M-34.3%
Q4 FY2022Dec 31, 2022$2.44M-29.9%
Q3 FY2022Sep 30, 2022$2.70M+23.5%
Q2 FY2022Jun 30, 2022$3.44M+83.7%
Q1 FY2022Mar 31, 2022$2.88M+64.4%
Q4 FY2021Dec 31, 2021$3.48M+90.7%
Q3 FY2021Sep 30, 2021$2.19M+80.1%
Q2 FY2021Jun 30, 2021$1.87M–
Q1 FY2021Mar 31, 2021$1.75M–
Q4 FY2020Dec 31, 2020$1.83M–
Q3 FY2020Sep 30, 2020$1.22M–

More Lucid Diagnostics figures

See a number that looks wrong?